Wound Management Technologies Reports Preliminary Financial Results For Year Ended December 31, 2015

ADDISON, TX / ACCESSWIRE / April 7, 2016 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced preliminary financial and operating results for year ended December 31, 2015.

Recent Operating Highlights

– Revenues increased 28% to $3.4 million for the full year 2015, compared to the prior year
– Significant focused reduction in operating overhead to streamline efforts
– Change in management with a focus on strategically growing revenues

“As we look ahead into 2016, we’d like to reflect on our accomplishments of this past year. Our distributor and representative base has continued to solidify and expand. By year end we hired four direct Regional Sales Managers to help support and grow accounts in the surgical and wound care markets. The Company remains on a growth trajectory that is being fueled by the advancement of our CellerateRX® products in the hospital and outpatient wound care markets. We have streamlined our operations and attracted great talent to the Company to help us execute on sales,” commented Deborah Hutchinson, President.

“Our expanded salesforce is having increased success with our surgical product line, supported by champions and key opinion leaders from a variety of surgeons in specialties including trauma, orthopedic, neurology, colorectal, vascular, plastic surgery, general surgery and more. Since its introduction, CellerateRX Surgical has been used in over 7,500 surgeries around the country. Our case studies and testimonials are continually expanding and show how CellerateRX helps to close complicated wounds in both healthy patients and patients with comorbidities (such as diabetes, smoking, and obesity). In 2016 we look forward to the release of published clinical studies that further demonstrate our product’s clinical and cost effectiveness.”

“As anticipated, in February 2016 we received FDA 510(k) clearance for a new product, HemaQuell™, a resorbable bone wax product that is a tamponade to control bleeding from bones during surgery, resorbing within two to seven days. We are now working with key opinion leaders to schedule first cases using HemaQuell and our sales team will commercialize HemaQuell in 2016. This adds to the royalty income that our Resorbable Orthopedic Products division adds to our bottom line.”

“In summary, we are extremely pleased to report another year of growth with 28% revenue growth over the prior year. We expect the momentum to continue into 2016 and beyond as our sales team continues to expand and grow. Our focus is solidly on sales and growth,” concluded Ms. Hutchinson.

About Wound Management Technologies

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its Wound Care Innovations subsidiary’s unique, patented collagen product line, CellerateRX(R) which is FDA-cleared for all wound types except 3rd degree burns. The Resorbable Orthopedic Products subsidiary owns a multi-faceted bone wax and bone void filler patent and markets products in the $1.5B biomaterials market and is anticipating new revenues from HemaQuell Resorbable Bone Wax. For more information visit our newly updated website, www.wmgtech.com.

Information about Forward-Looking Statements

The statements in the press release that relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:

Investor Relations
972-218-0935
info@wmgtech.com

SOURCE: Wound Management Technologies

ReleaseID: 438520